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ABSTRACT Systems biology offers considerable promise in uncovering novel pathways by which viruses and other microbial
pathogens interact with host signaling and expression networks to mediate disease severity. In this study, we have developed an
unbiased modeling approach to identify new pathways and network connections mediating acute lung injury, using severe acute
respiratory syndrome coronavirus (SARS-CoV) as a model pathogen.We utilized a time course of matched virologic, pathologi-
cal, and transcriptomic data within a novel methodological framework that can detect pathway enrichment among key highly
connected network genes. This unbiased approach produced a high-priority list of 4 genes in one pathway out of over 3,500
genes that were differentially expressed following SARS-CoV infection. With these data, we predicted that the urokinase and
other wound repair pathways would regulate lethal versus sublethal disease following SARS-CoV infection in mice. We validated
the importance of the urokinase pathway for SARS-CoV disease severity using genetically defined knockout mice, proteomic
correlates of pathway activation, and pathological disease severity. The results of these studies demonstrate that a fine balance
exists between host coagulation and fibrinolysin pathways regulating pathological disease outcomes, including diffuse alveolar
damage and acute lung injury, following infection with highly pathogenic respiratory viruses, such as SARS-CoV.
IMPORTANCE Severe acute respiratory syndrome coronavirus (SARS-CoV) emerged in 2002 and 2003, and infected patients de-
veloped an atypical pneumonia, acute lung injury (ALI), and acute respiratory distress syndrome (ARDS) leading to pulmonary
fibrosis and death. We identified sets of differentially expressed genes that contribute to ALI and ARDS using lethal and sub-
lethal SARS-CoV infectionmodels. Mathematical prioritization of our gene sets identified the urokinase and extracellular matrix
remodeling pathways as the most enriched pathways. By infecting Serpine1-knockout mice, we showed that the urokinase path-
way had a significant effect on both lung pathology and overall SARS-CoV pathogenesis. These results demonstrate the effective
use of unbiased modeling techniques for identification of high-priority host targets that regulate disease outcomes. Similar tran-
scriptional signatures were noted in 1918 and 2009 H1N1 influenza virus-infected mice, suggesting a common, potentially treat-
able mechanism in development of virus-induced ALI.
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Severe acute respiratory syndrome coronavirus (SARS-CoV)emerged in 2002 and 2003 inChina after evolving from related
virus species circulating in bats (1, 2). This novel group II corona-
virus infected over 8,000 people worldwide, with a mortality rate
of ~10% (3). In 2012, a novel human betacoronavirus from group
2c namedMiddle East respiratory syndrome coronavirus (MERS-
CoV) emerged in the Middle East. This virus causes severe pneu-
monia and renal failure with an approximately 55% mortality in
over 77 confirmed cases to date (4). SARS-CoV primarily infected
type II pneumocytes, which are normally responsible for produc-
tion of lung surfactants and function as the progenitor cells of type
I pneumocytes (5). Disease severity was heavily influenced by age
and other comorbidities, as mortality rates were50% in popu-
lations over 65 years of age.
Acute SARS-CoV infection resulted in denudation of airway
epithelial cells, often accompanied by the accumulation of debris,
which obstructed airway functions (6, 7). Progression to acute
lung injury (ALI) and the more severe form, acute respiratory
distress syndrome (ARDS), often involved an acute-phase diffuse
alveolar damage (DAD), which is characterized by exudates and
hyaline membranes in the lung alveoli (5). Biopsy and autopsy
findings from SARS patients within the early stages of infection
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revealed the presence of exudative-phase DAD along with in-
creased numbers ofmacrophages in the lung (1, 6).Many patients
also had lung hemorrhage, noncardiogenic pulmonary edema,
and/or hyaline membrane formation in the alveolar spaces. Pa-
tients with longer-term disease (10 days postinfection [dpi])
manifested with proliferative- or organizing-phase DAD that en-
compassed 25% to 100% of the lung (8). They also had signs of
lung fibrosis in both alveolar and interstitial spaces. SARS survi-
vors continue to show lingering effects of their illness with com-
plications including reduced lung elasticity and function (9).
ALI and the development of DAD may also occur with other
respiratory virus infections, including influenza virus (H5N1 or
H1N1-2009) and adult respiratory syncytial virus (RSV) infec-
tion, especially in the elderly (10–12).Much like SARS-CoV infec-
tion, disease progression is first associatedwith an exudative phase
of DAD, which may progress into organizing-phase DAD (13).
The presence of exudates in the lung, composed of fibrin and
proteinaceous material, blocks normal gas exchange (14). With-
out clearance of these exudates, lung pathology progresses toward
fibrotic disease with collagen deposition and conversion of the
exudates into fibrous tissue. Thus, ALI and ARDS represent a
commonbut poorly studied host response to virus-induced severe
lung disease.
Correlation-based gene coexpression network inference ap-
proaches are unbiased and powerful tools that can be used to
analyze large multidimensional data sets, including expression
microarray and proteomics data. Specifically, they capture com-
plex relationships between host gene expression patterns and
emergent correlative behaviors (15–17). These approaches posit
that genes and protein products are organized into functional
modules according to cellular processes and pathways. In this
work, we use weighted gene correlation network analysis
(WGCNA) methods to interpret the dynamic SARS-CoV-
mediated transcriptional response.WhileWGCNAhas previously
been applied to cancer, mouse, and yeast genetics, we use the
approach to enhance systems-based analysis of virus infection
(18–20). Key to this approach is the ability to discover systemic
gene expression patterns based on underlying correlation struc-
tures, which is not biased by existing knowledge of pathways or
interactions. WGCNA partitions gene expression into groups of
transcripts called subnetwork modules with highly correlated be-
haviors. It has been shown elsewhere that connectivity inferred
through WGCNA is a strong predictor of related biological func-
tion (21). A key feature of these subnetwork modules, or eigen-
genes, is that the most highly connected hub genes within the
module provide candidate mediators of disease (16, 17). We fur-
ther refined these candidates by modifying the tool to identify
enriched pathways associated with candidate lists, allowing us to
combine connectivity and predicted network structure with bio-
logical functions and known interactions within a hypothesis-
testing framework.
Pathogenesis in mouse-adapted-SARS-CoV-infected animals
closely mimics the pathologies that were observed in human pa-
tients (22), including age-dependent disease severity. To model
system-wide behaviors following SARS-CoV infection, we per-
formed a dose-response study that included biological sampling at
multiple time points, transcriptional and proteomic systems biol-
ogy data, and mathematical modeling algorithms to identify sig-
naling networks associated with progression from severe to lethal
disease outcomes. These data demonstrate the successful use of
highly refined modeling algorithms to identify and validate novel
genes and pathways that play critical roles in SARS-CoV patho-
genesis and the development of ALI following virus infection in
the lung.
In a healthy lung, fibrin levels are controlled through the action
of the enzyme plasmin and the urokinase pathway through extra-
cellular matrix (ECM) remodeling (23). ECM remodeling also
involves complex interactions between a number of metallopro-
teinases and their respective regulatory protein networks (24).
Disruption of the urokinase pathway is associated with fibrotic
lung disease or lung hemorrhage, depending on highly directional
signaling cascades. Tissue plasminogen activator (tPA or PLAT),
negatively regulated by Serpine1, is given as an anticlotting agent
to recent stroke patients to promote cleavage of plasminogen into
plasmin and enhance breakdown of fibrin clots (25). Although
ECMandwoundhealingpathway activation are known tobe impor-
tant in lung disease, these processes are largely unstudied in relation
to in vivo respiratory virus pathogenesis. In this work, we demon-
strate a critical role for the urokinase pathway in regulating severe
end-stage lung disease outcomes following SARS-CoV infection.
RESULTS
SARS-CoV infection model. To develop an unbiased strategy to
explore the molecular mechanisms regulating SARS-CoV patho-
genesis and host responses, we studied virus replication kinetics,
clinical disease severity, pathological changes, and variations in
host transcriptomics along with targeted proteomics using a dose
escalation study. The goal was to identify contrasting outcomes
for modeling the role of host responses in disease. Groups of 20-
week-oldC56BL6/J (B6)micewere infectedwith 102 to 105 PFUof
recombinant mouse-adapted SARS-CoV (MA15) or mock in-
fected (phosphate-buffered saline [PBS]). Clinical changes were
noted daily, and biological samples were collected at 0, 1, 2, 4, and
7 days postinfection (dpi) to allow for profiling of the different
phases of infection. Mice infected with the lowest dose, 102 PFU,
lost little if any weight and showed few clinical signs of disease
(Fig. 1A).Mice infectedwith 103 or 104 PFU experienced transient
weight loss and showed minor clinical signs of disease. Infection
with 105 PFU resulted in continuous weight loss with 30%
weight loss by day 7; at late time points, these animals showed
significant clinical disease, including hunched posture, ruffled fur,
decreased locomotion, labored breathing, and death.
Virus load in the lung was quantified by plaque assay and was
reflective of both the initial infectious dose and the overall repli-
cation kinetics.Mice infectedwith 102 PFUofMA15had relatively
lowor undetectable titers (Fig. 1B). Infectionwith the three higher
doses resulted in the highest titers at 1 or 2 dpi, an ~1-log drop in
titer at 4 dpi, and a decrease of several logs by 7 dpi, regardless of
changes in weight loss. Virus load was confirmed by quantitative
PCR (qPCR) for both virus genome and specific viral genes (see
Fig. S1A in the supplemental material; also data not shown). Con-
sistent with a previous report (22), minimal to no detectable virus
was found in the serumor other organs at 4 dpi (see Fig. S1B toD),
and no detectable virus was present in these other organs or serum
at day 7.
Pathological findings. Lung pathology varied by both infec-
tious dose and time but was not dependent on virus load. Full
histology scoring is available in Table S1A in the supplemental
material. At 1 dpi, infected mice showed few inflammatory cells
and healthy conducting airways, alveoli, and vasculature. By day 2,
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mice in all infection groups showed damage to the large and small
conducting airways of the lung in a dose-dependentmanner, con-
sisting of denuded patches of airway epithelial layers and apopto-
tic debris, often obstructing the small airways. At 4 dpi, all infected
animals had low levels of epithelial cell denudation and airway
debris along with mild thickening of the interstitial membranes.
Low-level perivascular cuffing was also present at this time point,
and moderate, sporadic hemorrhage was consistently observed in
mice infected with 103 to 105 PFU of MA15 at 4 dpi.
By 7 dpi, lung diseasewasmost pronounced in the parenchyma
in mice infected with a 105-PFU dose and included thickening of
the interstitial septum, inflammatory infiltrates including neutro-
phils, and pink proteinaceous exudates, typical of DAD (see
Fig. S1E in the supplemental material). Importantly, these mice
had clearly visible hyaline membranes, a characteristic of fatal
SARS-CoV infection in humans (26). These mice also showed
severe and complete lung hemorrhage at 7 dpi, whilemice infected
with 104 PFU had moderate but notable hemorrhage (see Ta-
ble S1A). Mice infected with lower doses had only mild to mod-
erate vascular cuffing and interstitial inflammation along with
sporadic and mild hemorrhage but were otherwise absent of se-
vere lung disease.
Global host expression patterns. Lung gene expression pat-
terns were compared between mice with each infection dose and
mock-infected mice to gain insight into SARS-CoV-induced lung
disease. Consistent with earlier reports (27), there was minimal
differential expression (DE) at the transcript level at 1 dpi (i.e.,
|log2 fold change [FC]| of 1.5 and false discovery rate [FDR]
adjusted P value of0.05), regardless of infectious dose (Fig. 2A).
However, the number of DE genes escalated with increasing dose
or number of days postinfection. Overlap of DE genes was deter-
mined between mice infected with 104 PFU and those infected
with 105 PFU. The maximum percentage of overlap in DE genes
was measured at 1 and 2 dpi, despite the low number of DE genes.
The least overlap between these doses was measured at 7 dpi
(Fig. 2B), with 23% of genes showing DE at 105 PFU but not at
104 PFU. We hypothesized that these genes with different expres-
sion patterns inmice infectedwith 105 PFU (here referred to as the
lethal dose) from those in mice infected with 104 PFU (here re-
ferred to as the sublethal dose) could provide insight into the
molecular mechanisms and host expression patterns that regulate
lethal versus sublethal disease following SARS-CoV infection.
Eigengene network analyses following SARS-CoV infection.
Gene expression patterns were compared between mice infected
with the sublethal dose and lethal dose using the WGCNA ap-
proach (28). In the consensus network analysis, 24 module eigen-
genes (clusters of genes with similar expression patterns over
time) were identified (23with statistically significant connectivity;
P value of0.0001 using permutation test) (Fig. 3A).Many of the
eigengenes represented groups of genes with similar expression
patterns and dynamics between the lethal and sublethal doses.We
chose to focus on one specific module eigengene that displayed
distinct dose dynamics, hypothesizing that the differences in tran-
script expression could explain the differential disease outcome.
The eigengene that we pursued, shown in blue and circled in
Fig. 3A, had significantly higher expression at 2, 4, and 7 dpi in
lethally infected mice than in sublethally infected mice (Fig. 3B;
expression patterns for the other statistically significant eigen-
genes can be found in Fig. S2 in the supplemental material). This
module was prioritizing based on differential expression between
doses at day 7 based on overall upregulation in the lethal dose
infection and differential module regulation when comparing
doses. Specifically, average log2 fold change (FC) was calculated
by subtracting the average log2 FC for each dose. Using this strat-
egy, we selected the bluemodule because it is strongly upregulated
for the lethal dose (1.28 average log2 FC) while the sublethal dos-
ing was only mildly upregulated (0.36 average log2 FC) and the
resulting average log2 FCwas 0.93 (an almost 2-fold difference).
This eigengene module was comprised of 760 differentially ex-
pressed transcripts.
When the unbiased gene list from the blue module was ana-
lyzed by theGeneGoMetacore knowledge base, the top functional
categories were related to cell adhesion, ECM remodeling, and
wound healing (see Table S2 in the supplemental material). The
same knowledge base was used to visualize the highest-priority
ECM remodeling signaling pathways containing proteins en-
FIG 1 SARS MA15 dose response. (A) Weight loss is shown as percent
starting weight over the course of a 7-day infection in 20-week-old B6 mice.
Mice infected with 102 to 104 PFU of SARS-CoV MA15 had low levels of
transient weight loss, while mice infected with 105 PFU showed increasing
weight loss over time. (B) Virus titer in the lung was quantitated by plaque
assay. The mean value of all samples with detectable virus in each group is
shown (three mice at 102 PFU and two each at 103, 104, and 105 PFU had
detectable virus by plaque assay at day 7; BLD, below the limit of detection of
100 PFU per lung).
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coded by the gene set with differential signaling in lethally or sub-
lethally infected mice (see Fig. S3). To further refine our candi-
dates, we assessed the connectivity and module membership
within known biological pathways. The full statistical analysis
workflow is described inMaterials andMethods, and a diagram of
the workflow is shown in Fig. S4. The urokinase pathway was the
most significantly enriched for bothmodulemembership (P value
 0.000793, odds ratio [OR] 8.31) and transcriptional connec-
tivity (P value 0.0126, 10,000 permutations),making it the ideal
target for validation. While the eigengenes themselves were not
priority ranked, the unbiased method that we used to prioritize
targets within the blue eigengene model could easily be applied to
other modules.
The urokinase pathway contributes to the broader ECM re-
modeling pathway shown in Fig. S3 in the supplemental material,
FIG 2 Dose-response differential gene expression. (A) Differential expres-
sion (DE) of transcripts for each dose is shown at each day postinfection. The
number of DE transcripts was greatest for sublethal (104-PFU) and lethal (105-
PFU) infections at day 2, with 2,091 and 2,251, respectively. In total across all
4 days, there were 3,138 unique DE transcripts for the 104-PFU infections and
3,683 for the 105-PFU infections. (B) The heat map shows the number of
overlapping transcripts for each time point in both sublethal- and lethal-dose
MA15 infections. Coloring represents the odds ratio or the effect size of each
overlap, and gray numbers within the cells are the numbers of common dif-
ferentially expressed (DE) transcripts. Analogous to differences in phenotype
between infection doses, the overlap is strongest at day 2 and weakest at day 7
postinfection.
FIG 3 Eigengene analysis. The consensus network is represented as a den-
drogram (A), and modules are shown as colors below. The blue module (cir-
cled in red) displayed distinct behavior for each dose (104 and 105 PFU), indi-
cating potential mediators of MA15 infection pathogenesis (B). The arrow in
panel A indicates the approximate location of Serpine1 and PLAT within the
blue module.
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and its members, including Serpine1, Serpine2, PLAT, and
PLAUR, along with other ECM remodeling genes, show signifi-
cantly higher expression at 7 dpi in the lethal dose than in the
sublethal dose (see Fig. S5A).While the urokinase pathway has not
previously been associated with respiratory virus infection, its in-
volvement in ischemic events andmetastatic cancers has beenwell
documented (29). Furthermore, fibrin turnover and alveolar co-
agulopathy are known to significantly contribute to the severity of
ALI following injury or chemical insult (30). Based on these fac-
tors, we explored the impact of the urokinase pathway on SARS-
CoV infection.
Acute lung injury following acute severe respiratory infec-
tion. Expanding on the identification of the urokinase pathway,
we examined whether conserved RNA expression signatures indi-
cated development of a procoagulant or profibrinolytic state after
SARS-CoV infection. Tissue factor, factor VIIa, and Serpine1 are
major factors responsible for the development of a procoagulant
and antifibrinolytic state in the alveoli (31, 32). Changes in alveo-
lar hemostatic balance and intra-alveolar fibrin deposition are also
stimulated by cytokine expression after ALI. Proinflammatory
(interleukin-1 [IL-1], tumor necrosis factor alpha [TNF-],
and IL-6) and profibrotic (transforming growth factor [TGF-],
connective tissue growth factor [CTGF], and platelet-derived
growth factor [PDGF]) cytokine transcripts were significantly el-
evated, starting by 4 dpi and through the course of the lethal
SARS-CoVMA15 infection (see Fig. S5B in the supplemental ma-
terial). In addition, genes associated with the induction of a pro-
coagulant state (thrombin, factor VIIa, factor Xia, factor XIIa,
PLAU, PLAT, tissue factor F2r) (32) and other fibrinolysin path-
way components were altered by infection. Both pro- and antifi-
brinolytic genes in the urokinase pathway showed increased ex-
pression in our SARS-CoV infection model, demonstrating the
complicated nature of this signaling cascade. Previous reports
show that it is rare for one branch of the urokinase pathway to
have altered regulation without host feedback loops adjusting the
expression of other pathway genes (33). In general, the transcripts
shown in Fig. S5B represent a lung with high levels of inflamma-
tory and fibrinolytic gene expression, and this transcriptional pic-
ture is supported by the hemorrhage observed in the lungs of
SARS-CoV-infected mice.
To increase our understanding of the changes in the lung fol-
lowing acute viral infection, we examined microarray data from
previously published respiratory infectionmodels of ARDS. Tran-
scriptional data from the lungs of 1918 influenza virus-infected
BALB/c mice showed similar patterns of differential expression in
the genes responsible for coagulation, surfactant production, and
fibrinolysis (see Fig. S6 in the supplemental material). Further-
more, B6mice infected with the 2009 H1N1 influenza virus strain
CA04 had high levels of proinflammatory, profibrotic, and uroki-
nase pathway gene expression relative to mock-infected mice
along with decreased surfactant expression (doses of 103 to
106 PFU [unpublished data]). Overall, these transcription signa-
tures are consistent with reported viral pathological and pro-
teomic findings, strongly supporting the development of altered
alveolar hemostatic balance seen during the early exudative phase
of DAD.
Urokinase pathway in SARS-CoV pathogenesis. To further
investigate the role of the urokinase and ECM remodeling path-
ways, we analyzed lung proteomics. Proteomics analysis revealed
that fibrin beta and gamma chains, factor VIII, and cytokeratins,
all major components of hyaline membranes (34, 35), have in-
creased expression in the lungs following both lethal and sublethal
SARS-CoV infection compared to mock infection (Fig. 4A). Sim-
ilarly, surfactant proteins, which typically protect against hyaline
membrane formation and lung injury (36), have reduced expres-
sion in both the lethal and sublethal doses of SARS-CoV com-
pared to uninfected controls. However, at late time points, several
of these same proteins sharply diverge between the lethal and sub-
lethal doses. Fibrin beta and gamma chain levels are increased in
abundance relative to mock infection only at day 7 in the lethal
infection. In contrast, fibrin chains continually decrease after 2 dpi
in sublethal infection. A similar pattern is observed with keratin 7,
with increased protein abundance observed in the lethal dose. To
further confirm these findings, we used a Martius scarlet blue
(MSB) stain to demonstrate the presence of fibrin deposition in
the lungs at day 7. Positive staining was observed in the lungs of
lethally infected mice but not in the lungs of mock-infected or
sublethally infected animals (Fig. 4B). Together, the proteomics
data are consistent with pathophysiological changes resulting in
increased fibrin deposition and hyaline membrane formation in
the lungs of lethally infected mice.
Fibrin is cleaved and degraded by plasmin, having been con-
verted from plasminogen by urokinase pathway members (23).
Analysis of plasminogen peptides revealed a distinct and signifi-
cant increase following a lethal dose of SARS-CoV (Fig. 4A). In
contrast, the sublethal infection resulted in an initial augmenta-
tion but then maintained a low level of plasminogen peptides
throughout the course of infection. It is important to note that
plasminogen and plasmin are indistinguishable using these pro-
teomics methods. Fibronectin, another component downstream
of plasmin activation, also demonstrated increased protein ex-
pression in the lethal dose compared to the sublethal dose at day 7.
These data are consistent with augmented PLAU/urokinase activ-
ity in the lethal dose despite maintaining similarly elevated levels
of Serpine1, an inhibitor of the urokinase pathway. Finally, dis-
eases associated with premature or excessive breakdown of fibrin
clots are characterized by hemorrhage and the accumulation of
fluid exudates in the alveoli. Consistent with the observation of
vascular leakage into alveolar spaces and the development of
DAD, levels of the serum protein albumin found in the lung were
significantly elevated in lethally infected mice (Fig. 4A).
Targeted knockout mice. To complete the systems biology
loop (broad study, model/hypothesis generation, and then testing
of the model), we selected a targeted member of the urokinase
pathway for validation studies. Genes within the blue module
were ranked according to their overall connectivity and agreement
with the module eigengene expression, and Serpine1 was the
highest-ranked urokinase pathway member (correlation with the
module eigengene [Kme] of 0.859). The approximate location of
Serpine1 within the blue module is highlighted in Fig. 3A. Ser-
pine1/mice infected with a sublethal dose of MA15 continued
to lose weight through day 7 postinfection (Fig. 5A) and showed
significantly more weight loss than did B6 controls at days 5 to 7
postinfection (P value of 0.05). Additionally, one Serpine1/
mouse died, suggesting a necessary and protective role for Ser-
pine1 in modulating SARS-CoV pathogenesis. Clinical disease in
Serpine1/ mice mirrored that in lethally infected B6 animals
(Fig. 1A), with severely decreased locomotion, hunched posture,
and labored breathing at late time points. Despite differences in
clinical symptoms, virus load in the lung showed no significant
Mechanisms of SARS-CoV-Induced Acute Lung Injury
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differences between knockout and wild-type (WT) mice (Fig. 5B)
at 4 or 7 dpi, demonstrating that Serpine1 had no influence on
virus replication dynamics. When B6 and Serpine1/mice were
infected with the lethal dose of SARS-CoV, the Serpine1/mice
succumbed to infection sooner than did the B6 controls (Fig. 5C)
(P value of 0.01), further indicating a protective role for Ser-
pine1 and the urokinase pathway in SARS-CoV-induced disease.
While 105 PFU is lethal in 20-week-old B6 mice, wild-type mice
rarely succumb before 7 dpi.
Examining lung sections, we observed cuffing of inflammatory
cells around the large airways and vasculature of all infected mice
at 4 dpi (see Table S1B in the supplemental material), which in-
creased by 7 dpi. At 4 dpi, there was mild interstitial membrane
thickening and low numbers of inflammatory cells were observed
in the alveolar spaces of all infected mice; by 7 dpi, disease in the
parenchyma had developed tomoderate levels. Gross hemorrhage
levels of the lung were noted at the time of tissue harvest. Ser-
pine1/ mice trended toward increased hemorrhage in their
lung tissue compared to B6 controls at day 4, and by 7 dpi, the
knockout mice exhibited significantly more lung hemorrhage
FIG 4 (A) Identification of urokinase and tissue remodeling pathway members. (A) Peptide levels from total lung homogenates were analyzed to determine
expression of select ECM and urokinase pathway proteins. Mock-infection values are shown by dashed lines, sublethal infection values are shown by gray lines,
and lethal infection values are shown by black lines. Significance values: *, P 0.05; **, P 0.01; ***, P 0.001; #, lethal dose significant at P 0.05. VWF, von
Willebrand factor. (B) Lung sections from 7-dpi lethally or sublethally infected mice or mock-infected mice were stained for the presence of fibrin using MSB
(Martius scarlet blue). Yellow staining indicates red blood cells, blue staining indicates connective tissue, and red staining indicates fibrin. Arrows point to
positive fibrin staining.
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FIG 5 Serpine1/mice are susceptible to SARS-CoV infection. (A) Serpine1/mice lost more weight than did B6 control mice when infected with 104 PFU
of SARS-CoVMA15 (P value of0.05 for Serpine1 versus B6 at days 5, 6, and 7 postinfection). (B) Serpine1/mice succumbed to infectionmore rapidly than
did B6 controls when infected with 105 PFU ofMA15 (** P value of0.01). (C) Lungmean virus load was quantitated by plaque assay. There was no statistical
difference in viral titers at 4 dpi; at 7 dpi,mostmice had lung titers below the limit of detection (BLD,100PFU; two Serpine1/mice and oneB6 controlmouse
with detectable virus). Independent replicate experiments confirmed significant differences inweight loss but nodifference in lung titer between Serpine1/ and
B6 controls at both 4 and 7 dpi (data not shown). (D) Representative histology images from Serpine1/ or B6 mouse lungs at 7 days postinfection show that
infected knockout mice had extensive hemorrhage after infection withMA15. Exudates are indicated by open arrows with dashed lines; hemorrhage is shown by
filled arrowswith solid lines. (E) Log2 fold change ratio of ARDS-related gene expression from the lungs of SARS-CoV-infected Serpine1/ and B6mice at 4 and
7 dpi (log2 fold changemean log2 FC [WT]mean log2 FC [knockout]). Green indicates that expression in Serpine1-knockout mice is lower than that in B6
mice, and red indicates that expression in Serpine1-knockout mice is higher than that in B6 mice.
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(P value of0.05 by Student’s t test) (Fig. 5D). Combined, these
data confirm our model prediction that Serpine1 and the uroki-
nase pathway play an important role in the pathogenesis of SARS-
CoV infection.
Examination of gene expression in the lungs of Serpine1/
mice and B6 controls showed that SARS infection causes greater
PLAT, IL-6, tissue factor (F3), and Serpine2 expression in the ab-
sence of Serpine1 (Fig. 5E). Serpine2 functions similarly to Ser-
pine1 in control of PLAT and PLAU activity. IL-1, Tgfb1, and
PLAU all had increased expression in Serpine1/ lungs at day 4
relative to B6 controls but decreased expression at day 7, while
Ptgs2 andTnf had decreased expression in the Serpine1/mice at
both time points. These data support the existing evidence of feed-
back loops within the urokinase pathway as well as confirming the
overall dysregulation of the urokinase pathway following SARS-
CoV infection. Combined, these transcriptional changes indicate
that SARS-CoV-infected Serpine1/mice had increased fibrino-
lytic activity in their lungs and a decreased inflammatory response
relative to B6 controls. A simplified schematic of the urokinase
pathway in the presence and absence of Serpine1 is shown in
Fig. 6A and B, illustrating how the lack of Serpine1 could lead to
increased PLAT andPLAUactivity and increased hemorrhage and
disease.
To further confirm the importance of the urokinase pathway in
SARS-CoV pathogenesis, we infectedmice deficient in PLAT, one
of the two plasmin-cleaving proteins that are activated by Ser-
pine1. PLAT expression was also highly connected to that of the
overall blue module with a Kme of 0.815. Mice deficient in PLAT
should have a complicated phenotype because of the ability of
PLAU to cleave fibrin and compensate in this system. Sublethally
infected PLAT/ mice showed a slight, but not statistically sig-
nificant (P  0.06), acceleration in recovery of weight loss com-
pared to B6 controls (see Fig. S7A in the supplemental material)
and a significant increase in exudates in the lung (P  0.05; see
Fig. S7E). In contrast, PLAT/mice infected with a lethal dose of
MA15 showed notable early mortality compared to B6 controls,
although those knockout mice that survived early infection went
on to recover (see Fig. S7B and C). Lethally infected PLAT/
mice also trended toward less hemorrhage in their lungs than did
B6 controls. B6 and PLATmice infectedwith equal doses ofMA15
had similar virus loads in the lung at both 4 and 7 days postinfec-
tion (see Fig. S7D), demonstrating thatmanipulation of the uroki-
nase pathway did not influence virus replication dynamics but
instead impacted the host response in regulating the development
and resolution of ALI.
DISCUSSION
In this study, we highlight an unbiased modeling approach using
systems biology to investigate viral pathogenesis and identify a
novel host pathway involved in SARS-CoV disease progression.
While wound healing and extracellular matrix remodeling path-
ways have previously been associated with lung disease (32), this
association had not extended into studies of acute respiratory vi-
rus infection. Our data suggest that dysregulation of the urokinase
pathway during SARS-CoV infection contributes to more severe
lung pathology and that Serpine1 plays a protective role following
infection. Similar changes in the urokinase, coagulation, and fi-
brinolysin pathway expression signatures are noted following
highly pathogenic SARS-CoV and influenza virus infections (see
Fig. S5B and S6 in the supplemental material), arguing for a con-
served role for these pathways in virus-induced end-stage lung
diseases, like ALI and ARDS.
The lack of well-defined statistical methods for organizing
complex data sets into prioritized modules has hampered the
power for systems-based discovery. While gene coexpression net-
works provide one approach to capture the complex relationships
between transcripts, the approach can also be integrated with
other types of quantitative data, like infection outcomes, patho-
FIG 6 Urokinase pathway model. (A) Representation of the unperturbed
urokinase pathway signaling pathway. (B) Without the presence of Serpine1,
an inhibitor of both PLAU/urokinase and PLAT/tPA, there is increased cleav-
age of plasminogen into the active plasmin and thus increased breakdown of
fibrin clots and hemorrhage compared to an unperturbed system. Red T
shapes indicate inhibition, and blue arrows indicate activation.
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logical findings, and clinical disease severity, resulting in a clearer
distinction between principal components (eigengenes) and bio-
logical processes. An important goal of these types of integrative
analyses is the deconstruction of large data sets into high-priority,
constructive gene signatures that provide predictive power for
downstreamanalysis and validation.However, these types of anal-
yses have rarely moved beyond simulations produced from exist-
ing data sets.
We have modified a WGCNA approach to cluster similarly
regulated genes into eigengene modules in order to compare and
contrast module behavior as a function of virus dose and disease
severity. We then developed strategies to prioritize targets for
downstream analyses at the level of larger pathway analyses which
were followed by analysis of specific genes. This approach was
applied to our virus infection data sets containing over 3,500 DE
genes. It resulted in the identification and characterization of four
highly prioritized genes in the urokinase pathway whose differen-
tial expression was significantly associated with increased disease
severity. We note that there are a number of enrichment ap-
proaches, such as gene set enrichment analysis (GSEA) (37), or
hypergeometric test-based approaches, such as GOStat (38),
which can identify genes behaving in coordinated ways to aid in
interpreting gene candidates. However, these approaches are of-
ten focused on differential expression in the context of functional
annotation. With our approach, we focus on de novo-inferred
connectivity and the distribution of the most highly connected
module members within canonical pathways. This allows for a
much more focused refinement of the candidate list and enables
the generation of direct hypotheses for perturbation testing
among the candidates.
Our unbiased transcriptomics analysis approach identified 24
eigengeneswith different expression patterns (Fig. 3A). The eigen-
gene network analysis and prioritization also identified several
highly ranked innate immune signaling components, including
MyD88, STAT1, and Ptgs2, as having high connectivity with the
severity of SARS-CoV disease outcome. Earlier studies have inde-
pendently demonstrated thatMyD88- and STAT1-knockoutmice
are highly susceptible to SARS-CoV pathogenesis and that block-
ing prostaglandin function protects old mice from SARS-CoV
pathogenesis (39–41). STAT1 signaling is known to affect cell cy-
cle and apoptotic processes, and STAT1-knockout mice are par-
ticularly sensitive to bleomycin-induced lung fibrosis with in-
creased collagen levels and enhanced fibroblast proliferation (42).
Together, these previous reports further confirm the efficacy of
our modeling approach.
To further validate our model, we analyzed genes from one
module eigengene with connections to wound healing and ECM
remodeling pathways, including the urokinase pathway, which
displayed dose-dependent expression changes. Both histology and
proteomic data demonstrated that urokinase activity increased in
a dose-dependent manner following SARS-CoV infection. To
complete a validation loop, we characterized disease outcomes in
Serpine1/ and PLAT/mice. The Serpine1/mice, deficient
in a major protein in the urokinase pathway, were significantly
more susceptible to SARS-CoV infection than were WT controls
in terms of bothweight loss and lung hemorrhage (Fig. 5A andD),
while the PLAT/ mice showed a mixed pathogenic phenotype
that suggested improved outcome but significant impairment of
lung function (see Fig. S7A and E in the supplemental material).
These data confirm predictions that the urokinase pathway and
ECM remodeling are important for regulating SARS-CoV patho-
genic outcomes and demonstrate the delicate balance between
development of hemorrhage and fibrosis following ALI. While
previous studies of SARS-CoV pathogenesis showed the presence
of fibrin in the lung following infection, the importance of Ser-
pine1 and the urokinase pathway in development of disease was
unknown. Furthermore, the use of unbiased methods to identify
the urokinase pathway as a regulator of SARS-CoV disease repre-
sents an important advance in analysis of microarray data.
ALI and itsmore severe form, ARDS, are devastating end-stage
lung diseases that can arise following a variety of acute insults to
the lung epithelium and occur frequently following infection with
SARS-CoV andH5N1 andH1N1 influenza viruses in humans (11,
43, 44). Despite significant advances in treatment options, the
overall mortality rates remain substantial and range between 30
and 60%, resulting in ~75,000 deaths in the United States and over a
million deaths globally each year (45). While the underlying molec-
ular mechanisms governing virus-induced ALI remain to be eluci-
dated, our transcriptomics, proteomics, modeling, and validation
approaches using targeted knockout mice have coalesced into a
model of altered hemostatic balance defined by the expression of
procoagulative and antifibrinolytic factors resulting in the induc-
tion of an exudative phase of DAD after infection. The urokinase
pathway regulates fibrinolytic and procoagulative responses de-
signed to prevent vascular permeability and hemorrhage (23, 29).
Fibrin levels dramatically increased following lethal SARS-
CoV MA15 infection (Fig. 4A and B). Excess fibrin was likely
mediated by Serpine1-driven inhibition of urokinase and tissue
type plasminogen activators (PLAU and PLAT) and by blockade
of plasmin activity by 2-plasmin inhibitor, whose transcripts are
elevated following SARS-CoV infection. We suggest that lethal
SARS-CoV infection overwhelms the normally protective, profi-
brinolytic signaling of the urokinase pathway, leading to overall
dysregulation, including increased Serpine1 expression, and se-
vere lung disease.While fibrin is required for normal wound heal-
ing, persistent and excessive intra-alveolar fibrin levels can con-
tribute to acute inflammatory and chronic interstitial lung disease.
Fibrin stimulates the production of profibrotic growth factors
(32), and many profibrotic cytokine transcripts, like TGF-,
CTGF, and PDGF, are elevated following SARS-CoV or influenza
virus infection in mice (see Fig. S5 and S6 in the supplemental
material) (46, 47). Pulmonary surfactant protein and transcript
signatures are also reduced following acute viral infection
(Fig. 4A) (see also Fig. S5) (48), potentially leading to collapse or
closure of alveoli and loss of lung compliance (changes in lung
volumes) (49). In combination, a high-fibrin/low-surfactant
intra-alveolar environment provides an ideal environment for fi-
broblast adherence and growth, resulting in collagen deposition
and development of lung fibrosis (50). Finally, fibrin and fibrin
breakdown products increase vascular permeability, stimulate
migration and proliferation of inflammatory cells, and promote
recruitment of neutrophils to the lung (51, 52). Although we can-
not absolutely ascribe this phenotype to elevation in the levels of
fibrin and fibrin breakdown products, fluorescence-activated cell
sorting (FACS) analysis shows significant increases in lung neu-
trophil counts, as a function of increasing SARS-CoV dose (data
not shown). More recent studies have also shown that Serpine1
inhibits neutrophil apoptosis (53), suggesting that neutrophil re-
cruitment and effector function likely contribute to more severe
disease outcomes following SARS-CoV MA15 infection. Similar
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findings have been reported with highly pathogenic influenza vi-
ruses, including H5N1 and 1918 influenza viruses (54).
Fibrin accumulation in the lung is a hallmark of ALI and
ARDS, and a reduced capacity to cleave and remove fibrin depos-
its corresponds with a poor clinical patient outcome (31). Nota-
bly, increased Serpine1 levels were measured in the blood of
SARS-CoV-infected patients during the 2002-2003 epidemic, and
increased Serpine1 expression has been measured in the lungs of
SARS-CoV-infected macaques (55, 56). Necropsy findings from
H5N1 influenza patients revealed accumulations of fibrin in the
lung along with pulmonary edema and other signs of DAD and
hemorrhage (57). Furthermore, 1918 and 2009 H1N1 influenza
virus-infected mice showed increased levels of urokinase pathway
transcripts (see Fig. S6 in the supplemental material; also data not
shown). The host response to Streptococcus pneumoniae also in-
cludes upregulation of Serpine1 expression to protect against
hemorrhage and ALI. The deubiquitinase CYLD provides critical
control of Serpine1 expression (58), and in the absence of CYLD,
infected mice develop lung fibrosis. Experiments using the mouse
model for pneumonic plague have shown that deletion of the bac-
terial plasminogen activator, which cleaves plasminogen and also
Serpine1, changes the course of disease and protects mice from
lethal lung injury (59). Combined, these data demonstrate the
critical balance of coagulative and fibrinolytic signaling in the lung
following injury and suggest a commonmodality for development
of pathogen-induced ALI and ARDS after microbial infection.
The systems biology approach promises to aid in our under-
standing of complex biological processes through the high-
throughput, unbiased analysis of broad data sets. Previous work
has demonstrated the ability to identify distinct transcriptomic
signatures predictive of the immune response to the yellow fever
and influenza vaccines (60, 61). Our approach highlights the abil-
ity to maintain statistical rigor and analytical prioritization that is
both driven by and focused on biological relevance and experi-
mental validation. Using this approach,mathematicalmodels and
their predictions, as well as the subsequent perturbations and re-
finement, allowed us to characterize the molecular mechanisms
that lead to the initiation and progression of infectious disease
pathogenesis. A comparative approachwithmultiple viruses, such
as SARS virus and highly pathogenic influenza virus, can identify
common pathways that lead to severe end-stage lung disease and
provide high-value targets for therapeutic approaches that address
multiple pathogens. These data demonstrate the successful use of
systems biology approaches to identify and then validate novel
genes and pathways that play critical roles in SARS-CoV patho-
genesis in the lung and suggest targeting urokinase and
coagulopathy-related signaling pathways as a therapeutic ap-
proach to treat virus-induced ALI.
MATERIALS AND METHODS
Viruses and cells. Recombinant mouse-adapted SARS-CoV (MA15) was
propagated on Vero E6 cells, and its titer was determined. For virus titra-
tion, half of the right lung was used to give PFU per lung using Vero E6
cells with a detection limit of 100 PFU (62). All experiments were per-
formed in a class II biological safety cabinet in a certified biosafety level 3
laboratory containing redundant exhaust fans by workers wearing per-
sonnel protective equipment, including Tyvek suits, hoods, and high-
efficiency particulate air (HEPA)-filtered powered air-purifying respira-
tors (PAPRs).
Animals. C57BL/6J (stock no. 000664), Serpine1/ (stock no.
002507), and PLAT/ (stock no. 002508) mice were obtained from the
Jackson Laboratory (Bar Harbor, ME). Mice were anesthetized with a
mixture of ketamine and xylazine and intranasally infected with either
50 l of phosphate-buffered saline (PBS) alone or MA15 (e.g., 102 to
105 PFU /animal). Animals were maintained in HEPA-filtered Sealsafe
cages (Techniplast, Buguggiate, Italy). All animal housing and care were
conducted in accordance with all University of North Carolina (UNC)-
Chapel Hill Institutional Animal Care and Use Committee guidelines.
Lung tissues from a total of 5 infectedmice were harvested at each dose on
days 1, 2, 4, and 7 postinfection in the dose-response study. Lung tissues
from a total of 4 infectedmicewere harvested at days 4 and 7 postinfection
in the knockout mouse studies. Mock-infected animals were age matched
and harvested at each time point.Weight loss significancewas determined
by Student’s t test (Microsoft Excel), and significance in survival data was
determined by the Mantel-Cox test (GraphPad). qPCR assays were used
to confirm the infection status of all mice. All mouse studies were per-
formed at the University of North Carolina (Animal Welfare Assurance
#A3410-01) using protocols approved by the UNC Institutional Animal
Care and Use Committee (IACUC).
Histological analysis andhemorrhage.Gross hemorrhage of lung tis-
sue was observed immediately after euthanasia and scored on a scale of 0
(no hemorrhage in any lobe) to 4 (extreme and complete hemorrhage in
all lobes of the lung). Lung tissues for histological analysis were fixed in
10% formalin (Fisher) for at least 7 days, tissues were embedded in par-
affin, and 5-m sections were prepared by the UNC histopathology core
facility. To determine the extent of inflammation, sections were stained
with hematoxylin and eosin (H&E) and scored in a blindedmanner that is
detailed in Text S1 in the supplemental material. Slides containing adja-
cent sections of lung tissue were stained with Martius scarlet blue (MSB)
to visualize fibrin by the UNC histology core. Images were captured using
an Olympus BX41 microscope with an Olympus DP71 camera.
RNA isolation, microarrays, quantitation of viral RNA species, full
details of statistical analysis of gene expression data, and data dissemina-
tion are all discussed in Text S1 in the supplemental material.
SARS-CoV infection response network inference.To identify groups
of host transcripts that showed coordinated regulation in response to
infection with SARS-CoV, we applied WGCNA (21, 63). The WGCNA
method detects signaling subnetworks ormodules consisting of groups of
genes that are highly connected according to a neighborhood proximity
metric called the topological overlap (TO). TO quantifies the degree of
shared network neighbors. Modules are represented as eigengenes by tak-
ing the first principal component of each set of module transcripts, which
describe most of the variance in the module gene expression. We have
adapted WGCNA into a workflow with three key steps: (i) de novo net-
work construction, (ii) consensus network analysis, and (iii) network en-
richment (see Fig. S4 in the supplemental material). The de novo network
construction and the derivation of signaling modules are described in
detail in Text S1 in the supplemental material. In addition to analysis of
the individual doses, we utilized a consensus approach to identify mod-
ules present across both networks (see Fig. S4). Two nodes should be
connected in a consensus network only if all of the input networks agree
on that connection. We define the consensus network similarity between
two nodes as the minimum of the input network similarities. This allows
identification of regulatory differences between two networks, even when
the resulting topology/modules are conserved.
Novel prioritization within network modules. We prioritized the
statistically validated host response modules to identify signaling events
that differed between doses at day 7 based on overall upregulation of the
105-PFU-dose treatment and differential module regulation when com-
paring treatments. Average log2 FCs were calculated across modules for
each dose.Modules were labeled as upregulated at day 7 if the average log2
FC was greater than zero. A  average log2 FC was calculated by subtract-
ing the average log2 FC for each dose at day 7. Network enrichment was
then performed in two stages: functional enrichment using gene ontology
(see Text S1 in the supplemental material for details) and connectivity
enrichment. To aid in the prioritization of the candidates to be validated
Gralinski et al.
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within themodules, we examined the connectivity distribution relative to
known canonical pathway membership within each module. We first
identified canonical pathways that intersected with a given WGCNA
module and then took the average TO connectivity between intersecting
members. Ten thousand random samplings of sets of genes of the same
size were used to derive a null distribution and determine if a given path-
way was enriched for TO connectivity. This provides information regard-
ing possible biological relevance to our putative candidates that had been
ranked within the module based on their similarity to the eigengene.
Proteomics samples. For proteomics analysis, SARS-CoV- or mock-
infected lung samples were collected andwashedwith 50mMammonium
bicarbonate buffer, homogenized in 1 ml of 8 M urea in 50 mM ammo-
nium bicarbonate buffer with glass beads for 60 s at 6,000 rpm, and then
incubated for 1 h at room temperature. Samples were then centrifuged at
5,000 rpm to remove debris and immediately stored at 80°C. At each
time point, analysis of individual mouse lungs provided intensity values
for proteins derived from multiple peptides. The mean intensity (abun-
dance) for each protein was then graphed as an average (n 5 for infec-
tion, n 3 formock infection) for each group at each time point. Missing
or absent values were not scored; however, if no value was observed in any
of the samples at a time point, the sample was registered with a single 0,
representing “not detected.” Full details of the proteomics sample prepa-
ration methods are in the supplemental material.
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